In short
This article discusses the ongoing clinical trials of Ginisortamab (also known as UCB6114), a promising drug being studied for the treatment of advanced solid tumors. The trials aim to assess the safety, effectiveness, and how the body processes this new medication. Researchers are exploring Ginisortamab both as a standalone treatment and in combination with other cancer therapies to determine its potential in fighting various types of advanced solid tumors.
At a glance
- Drug Name
- Ginisortamab (UCB6114)
- Condition Studied
- Advanced Solid Tumors
- Trial Phase
- Phase 1/2
- Administration Method
- Intravenous
- Study Design
- Open-label, multicenter, modular design with escalation & expansion modules
- Treatment Arms
- 1. Ginisortamab monotherapy; 2. Ginisortamab + trifluridine/tipiracil; 3. Ginisortamab + mFOLFOX6
- Primary Outcomes
- 1. Incidence of dose-limiting toxicities; 2. Incidence and severity of treatment-emergent adverse events
- Secondary Outcomes
- Ginisortamab concentration in blood over time
What is GINISORTAMAB?
GINISORTAMAB, also known as UCB6114, is a new drug being studied for the treatment of advanced solid tumors. Solid tumors are abnormal masses of tissue that don't contain cysts or liquid areas. They can occur in many parts of the body, such as the lungs, breast, colon, or prostate. When we say "advanced," it means that the cancer has spread from where it started to other parts of the body or is in a late stage.
Purpose of the Study
Researchers are conducting a study to learn more about GINISORTAMAB. The main goals of this study are to:
- Determine how safe the drug is for patients
- Understand how the drug moves through and is processed by the body (this is called pharmacokinetics or PK)
- See how effective the drug is at fighting tumors
The study is designed to test GINISORTAMAB both on its own (called monotherapy) and in combination with other cancer treatments that are already used as standard care.
How is GINISORTAMAB Administered?
GINISORTAMAB is given to patients through an intravenous (IV) infusion. This means the drug is delivered directly into the bloodstream through a vein. Patients in the study will receive pre-determined doses of the drug at specific times throughout the study period.
Combination Therapies
In addition to testing GINISORTAMAB on its own, researchers are also studying how it works when combined with other cancer treatments. These combinations include:
- GINISORTAMAB with trifluridine/tipiracil (TFD/TPI): TFD/TPI, also known as TAS-102 or Lonsurf®, is a combination of two drugs that is already used to treat some types of cancer. In this study, it's given as film-coated tablets.
- GINISORTAMAB with FOLFOX: FOLFOX is a chemotherapy regimen that includes three drugs: oxaliplatin, leucovorin (also called calcium folinate), and 5-fluorouracil (5-FU). This combination is commonly used to treat various types of cancer, especially colorectal cancer. In this study, FOLFOX is given as an IV infusion.
The purpose of testing these combinations is to see if GINISORTAMAB can enhance the effectiveness of these existing treatments.
Safety and Side Effects
A major focus of this study is to assess the safety of GINISORTAMAB. Researchers are closely monitoring for any side effects or adverse events that may occur. They are particularly interested in:
- Dose-limiting toxicities (DLTs): These are side effects that are severe enough to prevent increasing the dose of the drug. The study will look for these effects especially during the first 28 days of treatment.
- Treatment-emergent adverse events (TEAEs): These are any unfavorable medical occurrences that happen after starting the treatment. They could be new symptoms or diseases, or worsening of existing conditions. The researchers will monitor for these throughout the entire study period, which is expected to last an average of 12 weeks.
It's important to note that not all adverse events may be directly caused by the drug, but all are recorded and studied to ensure patient safety.
Monitoring Drug Levels
To better understand how GINISORTAMAB works in the body, researchers will take blood samples from participants at various times throughout the study. These samples will be used to measure the concentration of GINISORTAMAB in the blood. This information helps researchers determine how the drug is absorbed, distributed, and eliminated from the body, which is crucial for determining the right dosage and schedule for future treatments.